Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2004 (First Quarter of Fiscal 2005)
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.
Key Financial Metrics
| Metric | Q1 2005 (Dec 31, 2004) | Q1 2004 (Dec 31, 2003) |
|---|---|---|
| Revenues | $1,288.4 million | $1,185.1 million |
| Operating Income | $250.7 million | $168.5 million |
| Net Income | $195.4 million | $125.4 million |
| Diluted EPS (Continuing Ops) | $0.74 | $0.48 |
| Gross Profit Margin | 50.8% | 46.5% |
| Operating Cash Flow | $257.1 million | $196.2 million |
| Cash and Equivalents | $822.0 million | $534.6 million |
| Total Debt | $1,169.6 million | N/A (Balance Sheet data only) |
| Debt-to-Capitalization | 25.6% | 28.1% (Prior Quarter) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8.7% year-over-year. Excluding favorable foreign currency translation, organic growth was approximately 5.7%. International revenues grew 10.7% reported, or 4.7% at constant currency.
- Profitability Surge: Operating income increased significantly, driven by higher gross margins (up 430 basis points) and the absence of a $45 million charge recorded in the prior year related to blood glucose monitoring (BGM) product recalls and write-offs.
- Segment Performance:
- Medical: Revenues up 11% (8% constant currency); Operating income up $71 million to $163 million (excluding prior year BGM charges).
- Diagnostics: Revenues up 3%; Operating income up $5 million to $103 million.
- Biosciences: Revenues up 15% (11% constant currency); Operating income up $8 million to $37 million, driven by instrument sales (FACSCanto and FACSAria).
- Accounting Change: The company adopted SFAS No. 123(R) effective October 1, 2004, recognizing share-based compensation expense of $11.6 million in the current quarter, reducing diluted EPS by $0.03.
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit margins to improve by 30-40 basis points for fiscal 2005 (excluding share-based compensation and prior year charges). Selling and administrative expenses are expected to improve by 75-100 basis points as a percentage of revenue. R&D spending is anticipated to increase 12-15% for the full year.
- Capital Allocation: Capital expenditures for fiscal 2005 are projected between $300 million and $325 million. The company repurchased $112 million of common stock in the quarter, with authorization remaining for an additional 12.1 million shares.
- Divestiture: The Clontech unit (BD Biosciences) is classified as "Discontinued Operations" pending sale. Assets held for sale totaled $63.7 million.
- Risks and Contingencies:
- Legal: Ongoing litigation (product liability, patent infringement) could result in charges exceeding current reserves.
- Foreign Currency: Significant exposure to exchange rate fluctuations, partially hedged via options and forwards.
- Regulatory/Tax: Uncertainty regarding the repatriation of foreign earnings under the American Jobs Creation Act of 2004; potential tax cost estimated at 6-8% on repatriated amounts.
- Supply Chain: Fluctuations in raw material costs (e.g., resin prices) impacting cost of products sold.
Investor Verification Checklist
- Share-Based Compensation Impact: Verify the full-year impact of the new SFAS 123(R) adoption on earnings, estimated at $0.17 reduction in diluted EPS.
- Clontech Divestiture: Monitor the timeline and terms of the Clontech sale, currently reported as discontinued operations.
- Pension Funding: Note the $103 million in discretionary pension contributions made in Q1 2005 and Q1 2004, which significantly impacted operating cash flow.
- Foreign Currency Sensitivity: Assess the impact of currency fluctuations on future margins, as reported growth included a ~3% favorable FX impact.
- Debt Maturities: Review the redemption of the $100 million 8.7% Debentures in January 2005 and the status of the $900 million credit facility.